JP2015510393A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015510393A5 JP2015510393A5 JP2014553578A JP2014553578A JP2015510393A5 JP 2015510393 A5 JP2015510393 A5 JP 2015510393A5 JP 2014553578 A JP2014553578 A JP 2014553578A JP 2014553578 A JP2014553578 A JP 2014553578A JP 2015510393 A5 JP2015510393 A5 JP 2015510393A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- amino acid
- peptide according
- agent
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical group 0.000 claims 10
- 235000001014 amino acid Nutrition 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 210000004027 cells Anatomy 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 102000001253 Protein Kinases Human genes 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 229940079593 drugs Drugs 0.000 claims 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 3
- 108091000081 Phosphotransferases Proteins 0.000 claims 3
- 235000004279 alanine Nutrition 0.000 claims 3
- 239000004474 valine Substances 0.000 claims 3
- 241000894006 Bacteria Species 0.000 claims 2
- 108030004415 EC 2.7.11.1 Proteins 0.000 claims 2
- 102000001332 SRC Human genes 0.000 claims 2
- 101710009384 SRC Proteins 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 101700006583 AKT2 Proteins 0.000 claims 1
- 101700004058 AKT3 Proteins 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 210000000170 Cell Membrane Anatomy 0.000 claims 1
- 210000000805 Cytoplasm Anatomy 0.000 claims 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108060006633 Protein Kinases Proteins 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 108091006100 chimeric peptides Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
Claims (20)
- 癌細胞の成長を阻害するための単離又は精製されたペプチドであって、アミノ酸配列RxKxKxxxxR(配列番号5)を含み(式中、K及びRはそれぞれリジン及びアルギニンアミノ酸残基であり、各xは、独立して、アラニン(A)、バリン(V)、及びセリン(S)からなる群から選択されるアミノ酸である)、且つ10〜40アミノ酸の長さを有するペプチド。
- 各xアミノ酸が、独立してアラニン(A)又はバリン(V)である、請求項1に記載のペプチド。
- 各xアミノ酸がアラニン(A)である、請求項1に記載のペプチド。
- 各xアミノ酸がバリン(V)である、請求項1に記載のペプチド。
- アミノ酸配列RSKAKNPLYR(配列番号2)と50%の配列同一性を有する請求項1又は2に記載のペプチド。
- 前記アミノ酸配列RSKAKNPLYR(配列番号2)と40%の配列同一性を有する請求項1又は2に記載のペプチド。
- アミノ酸配列RxKxKxxxxR(配列番号5)からなる、請求項1〜6のいずれか一項に記載のペプチド。
- 10〜25アミノ酸の長さを有する、請求項1〜6のいずれか一項に記載のペプチド。
- c−Src及びAkt非特異的セリン/スレオニンプロテインキナーゼからなる群から選択されるキナーゼを阻害する、請求項1〜8のいずれか一項に記載のペプチド。
- 癌細胞の成長及び/又は増殖を阻害する薬剤であって、前記癌細胞の外側細胞膜を越えて前記細胞の細胞質内に入る前記ペプチドの通過を促進するための促進部分とカップリングされた請求項1〜9のいずれか一項に記載のペプチドを含む薬剤。
- キメラペプチドである、請求項10に記載の薬剤。
- 前記ペプチド又は薬剤を発現させるための、請求項1〜9のいずれか一項に記載のペプチド又は請求項10又は11に記載の薬剤をコードする単離核酸。
- 細胞において前記ペプチドを発現させるための、請求項1〜9のいずれか一項に記載のペプチドをコードする核酸インサートを含む発現ベクター。
- 請求項1〜9のいずれか一項に記載のペプチド、請求項10又は11に記載の薬剤、又は請求項13に記載の発現ベクターを、薬学的に許容可能な担体又は賦形剤と共に含む医薬組成物。
- 前記ペプチドが負荷された細菌由来のミニ細胞を含む、請求項14に記載の医薬組成物。
- 前記発現ベクターが負荷された細菌由来のミニ細胞を含む、請求項14に記載の医薬組成物。
- 細胞における少なくとも1つのプロテインキナーゼの活性の阻害における使用のための、請求項1〜9のいずれか一項に記載のペプチド、請求項10又は11に記載の薬剤、または、前記ペプチドをコードする核酸。
- 前記キナーゼが、c−Src及びAkt非特異的セリン/スレオニンプロテインキナーゼファミリーの少なくとも1つのキナーゼからなる群から選択される、請求項17に記載のペプチド、薬剤、または核酸。
- 前記ペプチドが、Akt2及びAkt3の少なくとも一方の活性を阻害する、請求項18に記載のペプチド、薬剤、または核酸。
- 哺乳動物における癌の予防又は治療に使用される、請求項1〜9のいずれか一項に記載のペプチド、請求項10又は11に記載の薬剤、又は前記ペプチドをコードする核酸。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2012900259 | 2012-01-24 | ||
AU2012900259A AU2012900259A0 (en) | 2012-01-24 | Agents for use in cancer therapy | |
AU2012904368 | 2012-10-06 | ||
AU2012904368A AU2012904368A0 (en) | 2012-10-06 | Anti-cancer peptides | |
PCT/AU2013/000045 WO2013110120A1 (en) | 2012-01-24 | 2013-01-24 | Peptide agents for cancer therapy |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015510393A JP2015510393A (ja) | 2015-04-09 |
JP2015510393A5 true JP2015510393A5 (ja) | 2016-03-17 |
JP6249447B2 JP6249447B2 (ja) | 2017-12-20 |
Family
ID=48872819
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014553578A Active JP6249447B2 (ja) | 2012-01-24 | 2013-01-24 | 癌治療用ペプチド剤 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9403877B2 (ja) |
EP (1) | EP2807180B1 (ja) |
JP (1) | JP6249447B2 (ja) |
CN (1) | CN104271590B (ja) |
AU (1) | AU2013202137B2 (ja) |
CA (1) | CA2862485C (ja) |
WO (1) | WO2013110120A1 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101644982B1 (ko) * | 2015-07-23 | 2016-08-02 | 주식회사 엔솔바이오사이언스 | 신규 펩타이드 및 그 용도 |
CN105294839A (zh) * | 2015-10-28 | 2016-02-03 | 上海大学 | 对新生血管形成有阻断功能的多肽化合物及其应用 |
CN105936642A (zh) * | 2016-07-09 | 2016-09-14 | 青岛大学 | 具有抑制癌细胞生长活性的肽及其应用 |
CN106084012A (zh) * | 2016-07-09 | 2016-11-09 | 青岛大学 | 具有抑制癌细胞生长活性的肽及其应用 |
CN105936643A (zh) * | 2016-07-09 | 2016-09-14 | 青岛大学 | 具有抑制癌细胞生长活性的肽及其应用 |
CN106167513A (zh) * | 2016-07-09 | 2016-11-30 | 青岛大学 | 具有抑制癌细胞生长活性的肽及其应用 |
CN106146620A (zh) * | 2016-07-09 | 2016-11-23 | 青岛大学 | 具有抑制癌细胞生长活性的肽及其应用 |
GB201706472D0 (en) * | 2017-04-24 | 2017-06-07 | Cancer Res Tech Ltd | Tumour-targeting peptide variants |
WO2019174610A1 (zh) * | 2018-03-14 | 2019-09-19 | 蔡立刚 | 一种溶瘤病毒、合成dna序列及其应用 |
KR20210021311A (ko) * | 2018-05-15 | 2021-02-25 | 인터크 펩타이드 테라퓨틱스 리미티드 | 활성화 제제 |
KR20210021984A (ko) | 2018-05-15 | 2021-03-02 | 인터크 펩타이드 테라퓨틱스 리미티드 | 펩타이드 활성화 제제 |
CA3120624A1 (en) * | 2018-11-30 | 2020-06-04 | Interk Peptide Therapeutics Limited | Polypeptides and methods for improving skin conditions |
CN110893236A (zh) * | 2019-10-09 | 2020-03-20 | 中山大学 | 溶酶体靶向的抗体药物偶联物及其应用 |
CN112646018B (zh) * | 2021-01-25 | 2023-04-28 | 井冈山大学 | 一种抑制肿瘤细胞增殖和转移的生物活性肽及其应用 |
AU2022328459A1 (en) * | 2021-08-20 | 2024-02-22 | Interk Peptide Therapeutics Limited | Compositions and methods for treating autoimmunity, including autoimmunity associated with cancer and cancer therapy |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030162956A1 (en) | 1997-04-07 | 2003-08-28 | Human Genome Sciences, Inc. | Leukocyte regulatory factors 1 and 2 |
US8119594B1 (en) | 1999-06-28 | 2012-02-21 | Inter-K Pty Limited | Method of modulating integrin mediated cellular activity and agents useful for same |
AU2001275423B2 (en) | 2000-06-09 | 2007-01-11 | Regulon, Inc. | Encapsulation of polynucleotides and drugs into targeted liposomes |
US6696546B1 (en) | 2000-11-06 | 2004-02-24 | The Trustees Of Columbia University In The City Of New York | Peptide that kills growing but not stationary cells |
AUPR230500A0 (en) * | 2000-12-22 | 2001-01-25 | University Of Newcastle Research Associates Limited, The | A method of modulating map kinase mediated cellular activity and agents useful in same |
AU2002240892A1 (en) | 2001-01-02 | 2002-07-16 | Centre National De La Recherche Scientifique | Protein-protein interactions in adipocyte cells |
US20030194798A1 (en) | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
AU2002347426B2 (en) | 2001-10-15 | 2007-05-10 | Engeneic Molecular Delivery Pty Ltd | Intact minicells as vectors for DNA transfer and gene therapy in vitro and in vivo |
CA2464542C (en) * | 2001-11-16 | 2015-01-20 | Genentech, Inc. | Composition comprising and method of using angiopoietin-like protein 3 angptl3 |
US7611885B2 (en) | 2003-06-24 | 2009-11-03 | Engeneic Molecular Delivery Pty, Ltd. | Pharmaceutically compatible method for purifying intact bacterial minicells |
EP1636385A4 (en) | 2003-06-24 | 2010-06-02 | Mirus Bio Corp | INHIBITION OF GENE FUNCTION BY IN VIVO DISTRIBUTION OF GENE EXPRESSION INHIBITORS BASED ON POLYNUCLEOTIDES IN MAMMALIAN CELLS |
WO2005037308A1 (en) * | 2003-10-17 | 2005-04-28 | Inter-K Pty Limited | Methods and agents for the treatment of cancer |
US7183257B2 (en) | 2004-04-14 | 2007-02-27 | The Brigham And Women's Hospital, Inc. | Use of RPL41 to treat infections and inhibit cancer |
WO2006029005A2 (en) | 2004-09-02 | 2006-03-16 | Oklahoma Medical Research Foundation | Promoter substitution for immunoglobulin therapy |
ATE470454T1 (de) | 2004-09-13 | 2010-06-15 | Genzyme Corp | Multimere konstrukte |
WO2006029981A1 (en) | 2004-09-13 | 2006-03-23 | Vib Vzw | Abin-mediated protection against lung inflammatory disease |
WO2006031996A2 (en) | 2004-09-14 | 2006-03-23 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Targeting viruses using a modified sindbis glycoprotein |
GB0520068D0 (en) | 2005-10-03 | 2005-11-09 | Cancer Res Technology | av peptide ligand |
US7912214B2 (en) | 2007-07-20 | 2011-03-22 | Amadeus S.A.S. | Method and system for generating and controlling the distribution and use of personal promotion codes by targeted customers |
WO2009103127A1 (en) * | 2008-02-22 | 2009-08-27 | Inter-K Pty Limited | Therapeutic peptides |
WO2009106073A2 (en) | 2008-02-28 | 2009-09-03 | Dako Denmark A/S | Mhc multimers in borrelia diagnostics and disease |
EP2362909A4 (en) * | 2008-09-30 | 2012-10-10 | Zirus Inc | MAMMALIAN GENES INVOLVED IN INFECTION |
AU2010215086A1 (en) * | 2009-02-23 | 2011-09-08 | Inter-K Pty Limited | Inhibition of multiple cell activation pathways |
-
2013
- 2013-01-24 AU AU2013202137A patent/AU2013202137B2/en active Active
- 2013-01-24 JP JP2014553578A patent/JP6249447B2/ja active Active
- 2013-01-24 WO PCT/AU2013/000045 patent/WO2013110120A1/en active Application Filing
- 2013-01-24 CA CA2862485A patent/CA2862485C/en active Active
- 2013-01-24 CN CN201380016372.7A patent/CN104271590B/zh active Active
- 2013-01-24 US US14/374,245 patent/US9403877B2/en active Active
- 2013-01-24 EP EP13740583.3A patent/EP2807180B1/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015510393A5 (ja) | ||
HRP20192314T1 (hr) | Pripravci faktora viii i postupci pripreme i njihove uporabe | |
NZ587105A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
JP2016222689A5 (ja) | 合成ペプチド及び乾燥粉末薬剤輸送システム | |
HRP20201081T1 (hr) | Inhibitorni peptidi porijeklom od trem-sličnog transkripta 1 (tlt-1) i njihove uporabe | |
WO2018067217A3 (en) | COMPOSITIONS COMPRISING SHORT PEPTIDES DERIVED FROM PEDF AND USES THEREOF | |
JP2015518818A5 (ja) | ||
JP2017537611A5 (ja) | ||
JP2011528896A5 (ja) | ||
JP2015517488A5 (ja) | ||
JP2012176978A5 (ja) | ||
JP2010506826A5 (ja) | ||
JP2017532343A5 (ja) | ||
BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
JP2011528895A5 (ja) | ||
NZ603200A (en) | Peptides and their use | |
JP2011528897A5 (ja) | ||
NZ708990A (en) | Method for activating helper t cell | |
WO2016145234A3 (en) | Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same | |
BR112012013139A2 (pt) | oligopeptídeos imp-3 e vacinas incluindo os mesmos | |
BR112013006088A2 (pt) | Construto de entrega isolado, e, composição farmacêuticapolinucleotídeo que encodifica um construtor de entrega, vetor de expressão, e célula hospedeira isolada" | |
JP2012529293A5 (ja) | ||
JP2014529399A5 (ja) | ||
UA100127C2 (ru) | Пептид cdh3 и лекарственное средство, содержащее его | |
JP2018023397A5 (ja) |